| Date | Title | Description |
| 15.09.2026 | End-to-End Drug Development: How an Integrated CRDMO Connects Discovery, CMC, and Manufacturing | SAN DIEGO, CA, UNITED STATES, September 15, 2026 /EINPresswire.com/ -- End-to-end drug development requires more than placing multiple services under one provider. A genuinely integrated model connects scientific work, CMC development, qual... |
| 10.09.2026 | Pharma Companies Turn to Strategic CDMO Partnerships as Development Needs Evolve | SAN DIEGO, CA, UNITED STATES, September 10, 2026 /EINPresswire.com/ -- Pharmaceutical companies are rethinking how they choose development and manufacturing partners. As pipelines expand into peptides, oligonucleotides, targeted protein deg... |
| 09.09.2026 | Why Promising Compounds Still Fail: Improving Translatability Earlier in Drug Discovery | Improving Translatability Earlier in Drug Discovery SAN DIEGO, CA, UNITED STATES, September 9, 2026 /EINPresswire.com/ -- Some compounds seem highly promising in early discovery, showing strong activity against the target and performing wel... |
| 08.09.2026 | What Are the Latest Advances in Molecular Glue Drug Discovery? | SAN DIEGO, CA, UNITED STATES, September 8, 2026 /EINPresswire.com/ -- In August 2026, the FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide), the first approved cereblon E3 ligase modulator (CELMoD), in combina... |
| 31.08.2026 | WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion | SHANGHAI, Aug. 31, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 i... |
| 28.08.2026 | Compliance, Not Technology, Is Biggest Hurdle for Chinese AI Firms Going Global, Lawyer Says | (Yicai) Aug. 28 -- Compliance, rather than technology, is often the first major obstacle Chinese artificial intelligence companies encounter when expanding overseas, according to a senior Chinese lawyer.
Broadening national security scrutin... |
| 19.08.2026 | Pharmaceutical Contract Manufacturing Market to Reach USD 311.95 Billion by 2030 | The global Pharmaceutical Contract Manufacturing Market is projected to grow from USD 209.90 billion in 2025 to USD 311.95 billion by 2030, registering a CAGR of 8.2% during the forecast period. Growth is being driven by the increasing outs... |
| 11.08.2026 | Peptide Synthesis Market Trends: Drug Development and Biopharmaceutical Innovation Driving Growth | The peptide synthesis market is witnessing strong growth as peptides gain increasing importance in pharmaceutical research, therapeutic development, diagnostics, and biotechnology. Peptide synthesis enables the production of customized pept... |
| 04.08.2026 | WuXi AppTec's Integrated CRDMO Model Shortens Discovery-to-IND Timelines for Biotechnology Partners | SAN DIEGO, CA, UNITED STATES, August 4, 2026 /EINPresswire.com/ -- Key Takeaways
Investigational New Drug (IND) submission requires coordinated decisions across biology, DMPK, bioanalysis, and chemistry, manufacturing, and controls (CMC).
... |
| 04.08.2026 | WuXi AppTec' s Support for Small and Emerging Biotech Companies: Three Global Examples | SAN DIEGO, CA, UNITED STATES, August 4, 2026 /EINPresswire.com/ -- Key Takeaways
WuXi AppTec brings together drug discovery, development, and manufacturing within one integrated platform.This gives small and emerging biotech companies acces... |
| 03.08.2026 | WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model | SHANGHAI, Aug. 3, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first ha... |
| 08.07.2026 | The Role of CROs and CDMOs in Supporting Global Drug Development | SAN DIEGO, CA, UNITED STATES, July 8, 2026 /EINPresswire.com/ -- A CRO/CDMO that can support global drug development should combine modality-specific technical expertise, global regulatory experience, scalable manufacturing, mature quality ... |
| 08.07.2026 | How Integrated CRO and CDMO Platforms Support End-to-End Drug Development | SAN DIEGO, CA, UNITED STATES, July 8, 2026 /EINPresswire.com/ -- Drug developers seeking end-to-end development support may consider several types of external partners, including integrated CRDMO platforms, full-service CROs, and specialize... |
| 07.07.2026 | Smart Compound Stewardship for DMPK: WuXi AppTec DMPK’s Automated Compound Management with Full-Process Traceability | SAN DIEGO , CA, UNITED STATES, July 7, 2026 /EINPresswire.com/ -- Leveraging over 15 years of laboratory operational expertise, WuXi AppTec DMPK has provided compound management services to thousands of pharmaceutical and biotechnology comp... |
| 03.07.2026 | Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence | CAMBRIDGE, Mass., July 3, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the ap... |
| 12.06.2026 | WuXi AppTec Builds a Flexible Global Manufacturing Network Around Customer Choice | WuXi AppTec's Middletown site, Delaware, U.S
WuXi AppTec's Couvet site, Switzerland
WuXi AppTec's Tuas site, Singapore SHANGHAI, SHANGHAI, CHINA, June 12, 2026 /EINPresswire.com/ -- As pharmaceutical companies increasingly seek resilient an... |
| 12.06.2026 | WuXi AppTec Gains After Suing US DOD, Buying Back USD147.8 Million of Own Shares | (Yicai) June 12 -- WuXi AppTec’s shares rose after the Chinese biotech firm said it is suing the United States Department of Defense for wrongfully adding it to a list of companies with alleged links to China’s military and disclosed that i... |
| 11.06.2026 | As New Drug Modalities Advance, WuXi AppTec Expands Global Capabilities for Peptides, Oligonucleotides and TPDs | SHANGHAI, SHANGHAI, CHINA, June 11, 2026 /EINPresswire.com/ -- The rapid rise of new therapeutic modalities — from peptides and oligonucleotides to targeted protein degraders (TPDs) and antibody-drug conjugates (ADCs) — is reshaping how med... |
| 10.06.2026 | WuXi AppTec: Global Partnerships Built on Strict Compliance and Transparency | SAN DIEGO, CA, UNITED STATES, June 10, 2026 /EINPresswire.com/ -- As a global company operating in a highly regulated pharmaceutical and life sciences industry, WuXi AppTec places compliance, transparency, and responsible business conduct a... |
| 10.06.2026 | WuXi AppTec: A Global, Independent, Public Company Accountable to Shareholders, Customers, and Regulators | SAN DIEGO, CA, UNITED STATES, June 10, 2026 /EINPresswire.com/ -- Over the past two decades, WuXi AppTec has grown alongside the global pharmaceutical and life sciences industry it serves. From a single lab to today’s multinational enterpri... |
| 05.06.2026 | WuXi AppTec Accelerates Global Manufacturing Expansion to Meet Rising Customer Demand | SHANGHAI, SHANGHAI, CHINA, June 5, 2026 /EINPresswire.com/ -- WuXi AppTec is accelerating a broad global manufacturing expansion across the United States, Europe, and Asia as customer demand for drug development and manufacturing services c... |
| 29.05.2026 | Mining Trumps Finance for Top Executive Pay at Chinese Mainland-Listed Firms | (Yicai) May 29 -- The mining industry became the highest-paying sector for executives at China's mainland-listed companies in 2025, overtaking the financial sector, as average executive compensation across the market continued to rise, acco... |
| 20.05.2026 | Which CRDMO is good for Global Drug Manufacturing? | SAN DIEGO, CA, UNITED STATES, May 20, 2026 /EINPresswire.com/ -- Key Takeaways
1.WuXi AppTec's integrated CRDMO platform enhances speed and efficiency in drug development by reducing operational handoffs, allowing companies to move therapie... |
| 19.05.2026 | WuXi AppTec Expands Global Manufacturing Capacity as Customer Demand Accelerates | WuXi AppTec’s Middletown site, Delaware, United States
WuXi AppTec’s Couvet site, Switzerland
WuXi AppTec’s Singapore site
WuXi AppTec’s Taixing site, China [New] SHANGHAI, SHANGHAI, CHINA, May 19, 2026 /EINPresswire.com/ -- WuXi AppTec, a ... |
| 18.05.2026 | WuXi AppTec Supports a More Connected Life Sciences Ecosystem Through Collaboration | SHANGHAI, SHANGHAI, CHINA, May 18, 2026 /EINPresswire.com/ -- The development of new medicines increasingly depends on coordination across a wide range of stakeholders. Biotech companies, pharmaceutical organizations, research institutions,... |
| 18.05.2026 | WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index | SHANGHAI, May 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Ind... |
| 18.05.2026 | Which CRO Is Good at Protein Degradation? | SAN DIEGO, CA, UNITED STATES, May 18, 2026 /EINPresswire.com/ -- Which CRO Is Good at Protein Degradation?
Key Takeaways
An idealCRO for protein degradation combines discovery biology, medicinal chemistry, drug metabolism and pharmacokineti... |
| 18.05.2026 | Which CDMO is good for Global Drug Manufacturing | SAN DIEGO, CA, UNITED STATES, May 18, 2026 /EINPresswire.com/ -- Key Takeaways
1.WuXi AppTec's integrated CRDMO platform enhances speed and efficiency in drug development by reducing operational handoffs, allowing companies to move therapie... |
| 18.05.2026 | WuXi AppTec’s CRDMO Model: Linking Research, Development, and Manufacturing Across the Drug Development Lifecycle | SHANGHAI, SHANGHAI, CHINA, May 18, 2026 /EINPresswire.com/ -- In today’s life sciences industry, moving a drug candidate from discovery to patient access remains a long, complex, and resource-intensive process. Research, development, and ma... |
| 18.05.2026 | WuXi AppTec Integrates Scale, Processes and Values to Safeguard Innovation | SHANGHAI, SHANGHAI, CHINA, May 18, 2026 /EINPresswire.com/ -- Embedding Protection Into Drug Discovery’s Intangible Assets
Much of a new medicine’s value exists long before it is packaged for patients. Long before a medicine reaches patient... |
| 30.04.2026 | WuXi AppTec Integrates Scale, Processes and Values to Safeguard Innovation | SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- Embedding Protection Into Drug Discovery’s Intangible Assets
Much of a new medicine’s value exists long before it is packaged for patients. Long before a medicine reaches patie... |
| 30.04.2026 | WuXi AppTec’s CRDMO Model: Linking Research, Development, and Manufacturing Across the Drug Development Lifecycle | SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- In today’s life sciences industry, moving a drug candidate from discovery to patient access remains a long, complex, and resource-intensive process. Research, development, and ... |
| 27.04.2026 | WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026 | Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY
Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion
Backlog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion
SHANGHAI, April 27, 2... |
| 17.04.2026 | WuXi AppTec's CRDMO Model: Integrating Research, Development, and Manufacturing into a Unified Platform | SAN DIEGO , CA, UNITED STATES, April 17, 2026 /EINPresswire.com/ -- In today’s life sciences landscape, the journey from discovery to patient access remains long, complex, and resource-intensive. WuXi AppTec, a global CRDMO (Contract Resear... |
| 14.04.2026 | What Drives WuXi AppTec’s 25-Year Compliance Record, and Why Does It Matter for Global Partnerships? | NATICK, MA, UNITED STATES, April 14, 2026 /EINPresswire.com/ -- As a global company operating in a highly regulated pharmaceutical and life sciences industry, WuXi AppTec places compliance, transparency, and responsible business conduct at ... |
| 14.04.2026 | How WuXi AppTec Safeguards Innovation Through Scale, Systems, and Culture | NATICK, MASSACHUSETTS, UNITED STATES, April 14, 2026 /EINPresswire.com/ -- In drug development, the most valuable asset is often invisible.
Before a medicine reaches patients, it exists as compound structures, experimental results, failed i... |
| 14.04.2026 | How WuXi AppTec Drives a More Connected and Collaborative Life Sciences Ecosystem | The WuXi Global Forum
Drug Metabolism and Pharmacokinetics SAN DIEGO , CA, UNITED STATES, April 14, 2026 /EINPresswire.com/ -- Since its foundation, WuXi AppTec has helped strengthen global life sciences collaboration by connecting innovato... |
| 02.04.2026 | CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala | SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. Th... |
| 23.03.2026 | Top 10 Leading Laser Cutting Machine Manufacturers: HGTECH Showcases High-Precision Innovation at FABTECH | WUHAI, HUBEI, CHINA, March 23, 2026 /EINPresswire.com/ -- The global manufacturing landscape is currently navigating a period of intensive recalibration. While the pursuit of operational efficiency remains constant, the focus has shifted to... |
| 14.02.2026 | US withdraws newly updated list of firms allegedly aiding China's military | WASHINGTON: The United States withdrew an updated list of Chinese firms allegedly aiding Beijing's military shortly after it was posted on Friday (Feb 13) with the addition of some of China's biggest tech companies, including Alibaba and Ba... |
| 19.01.2026 | WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership | SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the "A List" for leadershi... |
| 12.01.2026 | WuXi AppTec Issues Positive Profit Alert for the Full Year of 2025 | SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today issued a Positive Profit Alert for the full y... |
| 29.12.2025 | EcoFlow hires Huawei veteran Peter Tong ahead of US IPO push | Peter Tong, a former regional head of Huawei’s consumer business and a corporate partner at Hua Capital, has joined EcoFlow. His role reportedly ranks second only to founder and CEO Wang Lei.
36Kr sought confirmation from EcoFlow, but the c... |
| 15.12.2025 | D3 Bio Secures $108M to Advance Cancer Drug Trials Globally | D3 Bio, a Shanghai-based biotech, just raised $108 million. This Series B funding fuels late-stage trials. The focus? Elisrasib, a drug targeting KRAS G12C-mutant cancers. Trials will span the US, China, and Europe. The company aims for glo... |
| 14.12.2025 | D3 Bio: $108 Million Series B Raised To Fund Global Phase III Trials For Lead KRAS G12C Program | D3 Bio has raised $108 million in a Series B financing round to support late-stage clinical development of its lead oncology candidate and advance a broader pipeline of targeted and immuno-oncology programs.
The Shanghai-based clinical-stag... |
| 12.12.2025 | Temasek-backed D3 Bio secures $108 M Series B funding to advance global clinical programs | A $108 million Series B financing round has been completed, according to D3 Bio, a global clinical-stage biotechnology company dedicated to the discovery and development of novel oncology therapeutics.
A notable group of investors, includin... |
| 10.12.2025 | D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs | SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round.... |
| 10.12.2025 | D3 Bio Secures $108M in Series B Funding | D3 Bio, a Shanghai, China-based clinical-stage biotechnology company, raised $108M in Series B funding.
The round was led by IDG Capital and SongQing Capital. Existing investors WuXi AppTec’s Corporate Venture Fund, Temasek, HSG, MPCi, and ... |
| 29.10.2025 | Saudi Arabia's Global Health Exhibition 2025 Puts Medtech and AI Innovation in the Spotlight Leaders unveiled how data-driven innovation and space research are shaping healthcare in Saudi Arabia and b... | Being held from October 27-30 in Riyadh, the ongoing Global Health Exhibition (GHE 2025) has so far explored how the future for healthcare transformation is being driven through medical technology, AI innovation, investment and internationa... |
| 28.10.2025 | WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health | SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with ... |
| 27.10.2025 | WuXi AppTec: Integrating in Local European Ecosystems for Sustainable Growth | SHANGHAI, SHANGHAI, CHINA, October 27, 2025 /EINPresswire.com/ -- In the dynamic landscape of global biopharma, collaboration and a commitment to sustainable development have become pivotal. Companies that not only deliver innovative soluti... |
| 27.10.2025 | WuXi AppTec's Global Footprint: Serving Partners Across Asia, Europe, and North America | SHANGHAI, SHANGHAI, CHINA, October 27, 2025 /EINPresswire.com/ -- In recent years, the pharmaceutical and life sciences industry has placed greater emphasis on collaboration across borders. Innovation increasingly depends on research and de... |
| 26.10.2025 | WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance | Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY;
Revenue from Continuing Operations[1] Reached RMB12.04 Billion, Up 19.7% YoY
Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY;
Revenue from Continuing Operations Reached RMB32.45 Billion,... |
| 10.10.2025 | China Reviews JW Therapeutics’ Plan to Use Own Lentiviral Vector to Cut Cost of CAR-T Cancer Drug | (Yicai) Oct. 10 -- Chinese regulators have started reviewing an application by JW Cayman Therapeutics to substitute imported viral vectors for one of its CAR-T therapies with its own lentiviral vector, a change that could lower the cancer d... |
| 22.09.2025 | WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends | SHANGHAI, Sept. 22, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life scien... |
| 19.09.2025 | Bridging Innovation and Commercial Success: The Strategic Value of Integrated CRDMO Services | SHANGHAI, SHANGHAI, CHINA, September 19, 2025 /EINPresswire.com/ -- The Innovation Paradox in Modern Drug Development
The biopharmaceutical industry faces a paradox: scientific breakthroughs emerge rapidly, but translating them into therapi... |
| 19.09.2025 | WuXi AppTec Strengthens Global Trust With Excellent Regulatory Audit Record and Expanding Quality Certifications | SHANGHAI, SHANGHAI, CHINA, September 19, 2025 /EINPresswire.com/ -- In the pharmaceutical and life sciences industries, quality is paramount. A lapse in drug development or manufacturing quality can have catastrophic consequences, directly ... |
| 15.09.2025 | WuXi AppTec's New EU Batch Release Services: What This Means for European Biotech | WuXi AppTec
SHANGHAI, SHANGHAI, CHINA, September 15, 2025 /EINPresswire.com/ -- WuXi AppTec has achieved a key milestone for EU pharmaceutical market access: WuXi STA, its subsidiary, marks the official launch of EU batch release (Qualified... |
| 08.09.2025 | WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year | SHANGHAI, Sept. 8, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has receiv... |
| 06.08.2025 | WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year | SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced its inclusion ... |
| 08.07.2025 | WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities | SHANGHAI, July 8, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science... |
| 07.07.2025 | WuXi AppTec Receives MSCI ESG AAA Leader Rating | SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieve... |
| 27.06.2025 | WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity | SHANGHAI, June 27, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is delighted to announce that... |
| 19.06.2025 | WuXi AppTec: A Beacon of Innovation and Sustainability in Pharma | In the bustling world of pharmaceuticals, WuXi AppTec stands tall. This global powerhouse is not just a player; it’s a game-changer. With a unique blend of research and manufacturing services, WuXi AppTec empowers companies to deliver groun... |
| 18.06.2025 | WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets | SHANGHAI, June 18, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Ba... |
| 16.06.2025 | WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors | SHANGHAI, June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been recognized among the... |
| 28.04.2025 | WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY | Total Revenue Reached RMB9.65 Billion, Up 21.0% Year-over-Year; among which Revenue from Continuing Operations Reached RMB9.39 Billion, Up 23.1% Year-over-Year
Net Profit Attributable to the Owners of the Company Reached RMB3.67 Billion[1],... |
| 24.03.2025 | China’s biotech sector is undervalued given its AI-driven opportunities: Investor | - |
| 19.03.2025 | WuXi AppTec: A Phoenix Rising in the Pharmaceutical Landscape | WuXi AppTec is on the rise, much like a phoenix emerging from the ashes. The Chinese pharmaceutical services giant has recently forecasted a return to double-digit revenue growth, igniting investor enthusiasm and sending its stock soaring. ... |
| 18.03.2025 | WuXi AppTec Soars After Chinese Drug Services Giant Predicts Double-Digit Revenue Growth | (Yicai) March 18 -- WuXi AppTec's shares rose after the Chinese provider of research and development services to the pharmaceutical sector forecast annual revenue to return to double-digit growth this year after earnings fell last year.
WuX... |
| 17.03.2025 | WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs | Fourth-Quarter Revenue Reached RMB11,539 Million, Up 6.9% Year-over-Year
2024 Revenue Reached RMB39,241 Million, Up 5.2% Year-over-Year (Excluding COVID-19 Commercial Project of 2023)
Full-Year Net Profit Attributable to the Owners of the C... |
| 16.01.2025 | Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus | Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
By Patrick WingroveJanuary 16, 20257:24 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A general view of the... |
| 13.01.2025 | WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI) | SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industries, announced that it has joined... |
| 06.01.2025 | 150 new jobs as MSD agrees deal for WuXi Vaccines' Dundalk facility | MSD Ireland has agreed to acquire the WuXi Vaccines manufacturing facility in Dundalk, Co Louth for €500m.
The deal will increase the size of MSD's footprint in Ireland to eight locations, and the company plans to add 150 jobs at the 15,520... |
| 30.12.2024 | WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year | SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been re... |
| 28.12.2024 | WuXi's Strategic Retreat: Navigating U.S. Restrictions | In the ever-shifting landscape of global business, few stories capture the tension between opportunity and regulation like that of WuXi AppTec. This Chinese pharmaceutical giant is now selling its Advanced Therapies unit, a move that unders... |
| 27.12.2024 | Китайская фармкомпания WuXi продаст подразделение Advanced Therapies на фоне ограничений США | Компания WuXi, наряду с другими китайскими фирмами, оказалась в центре новых законов США, направленных на ограничение их бизнеса в Соединенных Штатах из-за проблем национальной безопасности.
В сентябре Палата представителей США приняла зако... |
| 24.12.2024 | China's WuXi to sell Advanced Therapies unit amid US restrictions | China's WuXi to sell Advanced Therapies unit amid US restrictions
By ReutersDecember 24, 20248:25 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
The logo of Chinese drug research and developmen... |
| 25.11.2024 | Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors | ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily ... |
| 12.11.2024 | Asia's Process Industries Set for Transformation with New Technology Showcase | The winds of change are blowing through Asia's process industries. A new event, the Process Innovation Asia Pacific (PIA), is set to launch in Singapore from November 19 to 21, 2024. This inaugural showcase aims to elevate the region's proc... |
| 12.11.2024 | WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment | SHANGHAI, Nov. 12, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been ranked #1 in the glo... |
| 06.11.2024 | MEGAROBO Unveils High-Content Cell Imaging System for Advanced Multidimensional Biological Analysis | BEIJING, Nov. 6, 2024 /PRNewswire/ -- MEGAROBO, a leading provider of advanced productivity tools for life sciences, has recently unveiled the CellVue™ T2000 high-content cell imaging system. The new cell imaging system is more than a digit... |
| 31.10.2024 | WuXi AppTec: A Beacon of Resilience in the Pharmaceutical Landscape | In the bustling world of pharmaceuticals, WuXi AppTec stands tall, a lighthouse guiding ships through turbulent waters. The company recently reported its financial results for the first three quarters of 2024, showcasing remarkable growth d... |
| 30.10.2024 | WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year | SHANGHAI, Oct. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Glo... |
| 28.10.2024 | Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-1... | Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year
Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-19 Commercial Projects, Up 4.6% Year-ove... |
| 11.09.2024 | The Rising Tide of Genomic Innovation: MGI's CycloneSEQ Technology and the Political Storm Surrounding Biotech | In the world of biotechnology, innovation is the lifeblood that fuels progress. MGI Tech Co., Ltd. has recently unveiled its latest advancements in nanopore sequencing technology, the CycloneSEQ-WT02 and CycloneSEQ-WY01. These products prom... |
| 07.09.2024 | Democrat to vote against bill restricting China's WuXi Biologics, BGI | Boards, Policy & RegulationHuman Rights
Democrat to vote against bill restricting China's WuXi Biologics, BGI
By Karen FreifeldSeptember 7, 20243:30 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Emai... |
| 31.07.2024 | WuXi AppTec: Navigating Challenges with Steady Growth in 2024 | In the turbulent waters of the pharmaceutical and life sciences industry, WuXi AppTec has managed to keep its ship afloat. The company’s recent financial results for the first half of 2024 reveal a narrative of resilience and strategic grow... |
| 29.07.2024 | Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ ... | Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year
Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year
Ne... |
| 29.07.2024 | Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ ... | Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year
Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year
Ne... |
| 15.05.2024 | Chinese biotech crackdown would reset U.S. drug development | figcaption>span]:font-sans">
Lawmakers in the House of Representatives on Wednesday are expected to set in motion a massive reordering of how U.S. pharmaceuticals are developed and made, by advancing a contracting ban on five key... |
| 29.04.2024 | WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations | Revenue Reached RMB7,982 Million; Excluding COVID-19 Commercial Projects, Down 1.8%
Net Profit Attributable to the Owners of the Company Reached RMB1,942 Million; Diluted Earnings per Share (EPS) Reached RMB0.66
Adjusted Non-IFRS Net Profit... |
| 18.03.2024 | WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time | Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6%
Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted Earnings per Share (EPS) Increased 14.... |
| 12.03.2024 | Drug Discovery Market Size, Share And Growth Analysis For 2024-2033 | Drug Discovery Global Market Report 2024 – Market Size, Trends, And Forecast 2024-2033
The Business Research Company’s Drug Discovery Global Market Report 2024 – Market Size, Trends, And Forecast 2024-2033
It will grow to $192.2 billion in ... |
| 06.03.2024 | US Senate Debates Bill Targeting Chinese Biotech Giants WuXi Apptec, BGI Over National Security Concerns | Quincy Jon, Tech Times 06 March 2024, 08:03 am
In a significant development on Capitol Hill, a groundbreaking bill in the U.S. Senate is poised for its inaugural examination in Congress on Wednesday.
This legislation, strategically crafted ... |
| 04.03.2024 | Pharmaceutical Manufacturing Market Projected to Grow at 7.8% CAGR, Reaching $863.6 Bn by 2030 | Vantage Market Research | Vantage Market Research
Pharmaceutical Manufacturing Market Size, Share, Industry Trends, Growth, and Opportunities Analysis by 2030 WASHINGTON, D.C, DISTRICT OF COLUMBIA, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- The Global Pharma... |
| 20.02.2024 | WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma | AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer.
PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi A... |
| 30.10.2023 | WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth | Revenue of RMB10,670 Million in the Third Quarter, Single Quarter Revenue Back to over RMB10 Billion; Revenue of RMB29,541 Million in the First Three Quarters, Up 4.0% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 23.4%
Net Pro... |
| 31.07.2023 | WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022 | Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 39.5%
Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 2... |
| 24.04.2023 | WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022 | Revenue Up 5.8% Year-Over-Year to RMB8,964 Million
Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB2,168 Million
Diluted Earnings per Share (EPS) Up 35.8% Year-Over-Year to RMB0.72
Adjusted Non-IFRS Net Profit... |
